Status:

COMPLETED

Isoproterenol Challenge to Detect Arrhythmogenic Right Ventricular Cardiomyopathy

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Conditions:

Arrhythmic Right Ventricular Cardiomyopathy

Eligibility:

All Genders

Brief Summary

This study will examine the usefulness of a new test called an isoproterenol challenge in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and family members who may have the disea...

Detailed Description

Arrhythmogenic right ventricular cardiomyopathy (ARVC) formerly referred to as arrhythmogenic right ventricular dysplasia (ARVD) is a familial hetergenous clinical and molecular disease characterized ...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Patients with ARVC:
  • Either gender, aged greater than 5 years.
  • The presence of two major criteria; one major and two minor criteria; or four minor criteria from separate diagnostic categories.
  • Normal Volunteers:
  • Age and gender matched with ARVC patients, age greater than 18 years.
  • No known cardiac disease.
  • Normal EKG, normal echocardiogram, normal Bruce protocol treadmill exercise test.
  • Family Members of Patients with ARVC:
  • Either gender, aged greater than 5 years.
  • A proband with ARVC
  • EXCLUSION CRITERIA:
  • Patients with ARVC:
  • Pregnancy or lactation excludes tests with potential risk, e.g. radiation, isoprenaline, MRI, but does not exclude 12-lead ECG and echocardiogram.
  • Coronary artery disease.
  • Known infiltrate or congenital heart disease that could mimic the appearances of ARVC.
  • Asthma prevents participation in Isoproterenol infusion.
  • Any other condition that would prevent participation in the study.
  • Normal Volunteers:
  • Pregnancy or lactation.
  • Asthma.
  • Coronary artery disease, hypertension, diabetes, hypertrophic cardiomyopathy, or other known cardiomyopathy.
  • Known infiltrative or congenital heart disease that could mimic the appearances of ARVC.
  • Any Acute or chronic illness.
  • Chronic drug therapy.
  • Family Members of Patients with ARVC:
  • Pregnancy or lactation excludes tests with potential risk, e.g. radiation, isoprenaline, MRI, but does not exclude 12-lead ECG and echocardiogram.
  • Coronary artery disease.
  • Known infiltrative or congenital heart disease that could mimic the appearances of ARVC.
  • Asthma prevents participation in Isoproterenol infusion.
  • Any other condition that would prevent participation in the study.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2004

    Trial Type :

    OBSERVATIONAL

    End Date :

    December 1 2005

    Estimated Enrollment :

    160 Patients enrolled

    Trial Details

    Trial ID

    NCT00083395

    Start Date

    May 1 2004

    End Date

    December 1 2005

    Last Update

    March 4 2008

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center (CC)

    Bethesda, Maryland, United States, 20892

    Isoproterenol Challenge to Detect Arrhythmogenic Right Ventricular Cardiomyopathy | DecenTrialz